Full-Time

Ophthalmology Field Director

Medical Science Liaisons

Posted on 9/8/2026

Biogen

Biogen

5,001-10,000 employees

Develops therapies for neurological disorders

Compensation Overview

$222k - $305k/yr

+ Cash bonus + Equity incentives

Remote in USA

Remote

Remote within the United States, with travel required 60% of the time, including overnight and occasional weekend travel.

Bachelor's, PhD

Category
Biology & Biotech
Required Skills
Veeva

Get referred to Biogen

See people who can refer or advise you

Requirements
  • At least 7 years of Medical Affairs experience, including Medical Science Liaison experience.
  • An advanced scientific or clinical degree is required, such as an MD, PhD, PharmD, or DNP.
  • Demonstrated leadership and management of effective Medical Affairs teams.
  • Excellent communication, formal presentation, and organizational skills, with the ability to manage several projects simultaneously.
  • Ability to travel 60% of the time, including overnight and occasional weekend travel.
  • A valid driver's license, an acceptable driving record, and authorization and ability to drive a company-leased vehicle or rental are required.
Responsibilities
  • Collaborate with Medical Directors, brand teams, clinical partners, and cross-functional stakeholders to develop and implement regional field medical strategies.
  • Establish and monitor key performance indicators measuring Medical Science Liaison impact and execution against medical and brand strategy.
  • Maintain an understanding of the therapeutic area, Biogen products, competitive landscape, and evolving regulatory and treatment guidelines to inform field strategy.
  • Prioritize and reprioritize field activities in response to scientific, regulatory, or market changes.
  • Lead the operating rhythm for field metrics and key performance indicator dashboards to support performance management and data-driven coaching.
  • Manage, coach, and develop Medical Science Liaisons through territory coaching and biannual territory reviews.
  • Ensure Medical Science Liaisons understand medical strategy, align engagement plans, and execute against defined key performance indicators and expectations.
  • Be accountable for team performance and foster an inclusive, high-engagement culture.
  • Ensure compliant collection of high-quality, strategically aligned Voice of Key Opinion Leader insights.
  • Oversee use of field tools and systems, including Veeva and OLA, and ensure healthcare provider targeting and activity documentation align with medical strategy and compliance requirements.
  • Drive adoption of approved tools, processes, and best practices that improve field efficiency, insight quality, and scientific impact.
  • Communicate medical insights to internal stakeholders to inform cross-functional strategy and tactical planning.
  • Serve as the primary regional field medical liaison across Medical, MDO, and cross-functional partners.
  • Communicate the value proposition of the medical strategy to internal leadership and stakeholders.
  • Lead, educate, and mentor internal stakeholders on therapeutic-area insights, strategic trade-offs, and the impact of medical decisions on enterprise goals.
  • Contribute to cross-therapeutic-area best-practice and lessons-learned sharing.
  • Manage and coach a team of professionals in support of Medical Affairs strategy and execution.
Desired Qualifications
  • Medical strategy experience.
  • Doctoral-level degree, such as an MD, PhD, PharmD, or DNP.
  • Clinical experience and subject-matter expertise in ophthalmology.
  • At least 2 years of experience managing field-based pharmaceutical or biotechnology industry employees.
  • Experience navigating an ultra-competitive disease state.

Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1978

Get referred to Biogen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Leqembi U.S. autoinjector launched in 2026, expanding home dosing and adoption.
  • Q2 2026 revenue reached $2.74 billion, and growth portfolio rose 24% year over year.
  • Biogen expects at least $250 million Apellis synergies by end-2027, lifting margins.

What critics are saying

  • Biogen cut most Apellis research on June 26, 2026, exposing brittle pipeline discipline.
  • Biogen faces Sandoz SPINRAZA patent trial in April 2027, threatening franchise economics.
  • Biogen's legacy MS sales fell 13% in Q2 2026, risking earnings erosion through 2027.

What makes Biogen unique

  • Biogen pairs neuroscience leadership with Eisai's LEQEMBI and Stoke's zorevunersen collaborations.
  • Biogen's 2026 growth portfolio now exceeds legacy MS revenue, proving franchise diversification.
  • Biogen bought Apellis in 2026, adding Syfovre and Empaveli to rare-disease commercial scale.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-10%

1 year growth

-10%

2 year growth

-10%
USA Herald
Sep 8th, 2026
Biogen MS drug monopoly suit survives as judge rejects dismissal bid.

Biogen MS drug monopoly suit survives as judge rejects dismissal bid. 0 Comments An Illinois federal judge on Tuesday kept alive a high-stakes antitrust battle, refusing to dismiss Walgreens and Kroger's lawsuit that accuses Biogen Inc. of illegally throttling competition for its multiple sclerosis drug Tecfidera. U.S. District Judge April Perry ruled from the bench in Chicago that the pharmacy giants have now alleged enough to show they "suffered a concrete injury as a result of Biogen's conduct." Perry had earlier granted Biogen's dismissal motion in February, finding Walgreen Co. and The Kroger Co. failed to demonstrate how the drugmaker's alleged formulary manipulation scheme produced a viable antitrust injury. This time the retailers cleared the bar. Allegations of market manipulation. Walgreens and Kroger contend the purported scheme forced them and their wholesalers to purchase and dispense far more of Biogen's costly brand-name Tecfidera than cheaper generic rivals. Their amended complaint states they run pharmacies in most states that either mandate or permit automatic substitution of a brand drug with a generic when the switch lowers patient costs. Biogen's alleged tactics, they claim, locked them into stocking and handing out the pricier branded version instead. Judge Perry acknowledged Tuesday that she, like Biogen, would have "preferred and expected to see" sharper, more explicit allegations. Yet "neither of us have the job of authoring the complaint." The revisions, she said, now allow a plausible injury to be reasonably inferred from the claim that the chains had to buy more of the higher-priced branded drugs. She ordered Biogen to respond to the complaint by Oct. 8. Coupons, formularies and a next-generation push. The pharmacy operators allege Biogen paid pharmacy benefit managers to rewrite certain health-plan formularies so that MS patients faced essentially identical out-of-pocket costs for branded Tecfidera or a competing generic. Biogen also handed insured patients coupons that made the brand appear cheaper than generics and scrambled to shift the market toward its "next-generation" drug Vumerity before generic Tecfidera could reach shelves, according to the suit. The prior complaint was tossed partly because neither plaintiff claimed it sold to any patients touched by the contested formularies or operated in states enforcing the substitution laws. While the alleged manipulation reached them by ripple effect, the judge had ruled they needed tighter facts to establish antitrust standing. Walgreens and Kroger are represented by Scott E. Perwin, Lauren C. Ravkind, Anna T. Neill and Trevor Scheetz of Sperling Kenny Nachwalter LLC. Biogen is represented by Lin W. Kahn, William D. Coglianese, Daniel Johnson, Eddie Hasdoo and Julie E. McEvoy of Jones Day.

Yahoo Finance
Sep 3rd, 2026
Leqembi subcutaneous formulation approved in China as first at-home Alzheimer's therapy

Eisai and Biogen announced that China's National Medical Products Administration approved the subcutaneous formulation of LEQEMBI (lecanemab) for early Alzheimer's disease. This marks the first anti-amyloid therapy in China enabling at-home administration. The approved regimen involves 500mg given once weekly as two consecutive 250mg injections using an autoinjector. The application received priority review designation after submission in January 2026. Launch is planned during Eisai's fiscal year ending March 31, 2027. The subcutaneous formulation takes approximately 15 seconds per injection, significantly reducing time compared with intravenous infusions. Patients can administer treatment at home weekly, or alternatively receive intravenous administration every two weeks in hospital settings. Switching between administration methods is permitted during treatment. The approval aims to reduce clinic visit burden for patients and caregivers whilst potentially decreasing healthcare resources associated with intravenous dosing.

Yahoo
Sep 1st, 2026
Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress.

Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress. Fiona Craig Updated Tue, September 1, 2026 at 7:00 AM PDT Stoke Therapeutics (NASDAQ:STOK) and Biogen (NASDAQ:BIIB) said they will present clinical data for zorevunersen, their investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress in Athens, Greece, from September 5 to 9. The presentations will include the first disclosure at a medical meeting of four-year results from ongoing Phase 1/2a open-label extension studies. According to the companies, improvements in cognition and behaviour were sustained through four years alongside reductions in seizures and a generally well-tolerated safety profile. New sub-analyses will also examine the treatment's effects on the most severe seizure types and patient quality of life. These findings are based on company-reported clinical data and zorevunersen remains investigational. Majority of patients remain in extension studies. A total of 81 patients were enrolled in the Phase 1/2a studies, with 93% subsequently continuing into one of two open-label extension studies. At the four-year data cutoff, 77% of those patients remained enrolled. More than 930 doses of zorevunersen had been administered as of July 31, 2026. Elevated cerebrospinal fluid protein levels were observed in approximately 94% of patients, with 59% classified as treatment-emergent adverse events. According to Stoke and Biogen, no serious clinical manifestations or cases of hydrocephalus were reported. The clinical significance of the reported findings remains subject to further evaluation, including results from ongoing late-stage development. Zorevunersen targets the SCN1A gene. Zorevunersen is an antisense oligonucleotide designed to increase production of functional NaV1.1 protein by targeting the unaffected copy of the SCN1A gene. Mutations in SCN1A are associated with most cases of Dravet syndrome. The investigational therapy has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, as well as orphan drug designation from both the FDA and the European Medicines Agency. These designations are intended to support the development of qualifying treatments and do not constitute regulatory approval. Phase 3 EMPEROR study underway. Stoke Therapeutics and Biogen are currently evaluating zorevunersen in the global Phase 3 EMPEROR study, with results anticipated in the third quarter of 2027. The timing represents the companies' current expectation and remains subject to the progress of the clinical trial. Under the companies' collaboration agreement, Stoke retains commercialization rights for zorevunersen in the United States, Canada and Mexico, while Biogen holds exclusive rights in the rest of the world. Zorevunersen has not been approved by any regulatory authority, and its safety and efficacy remain under clinical investigation. Stoke Therapeutics stock price Biogen stock price

Yahoo Finance
Aug 30th, 2026
Josh Brown picks Incyte and Biogen as top healthcare stocks outside AI capex trend

Josh Brown, CEO of Ritholtz Wealth Management, named Incyte and Biogen as top healthcare stock picks on CNBC's Halftime Report. Brown said he wanted to highlight stocks unrelated to AI and data centre spending themes. Incyte, up 22% this year, develops drugs for blood cancers, solid tumours and inflammatory skin diseases. In July, revenue rose 38% year over year whilst net product sales jumped 40%, both beating Wall Street estimates. Its key product Jakafi saw sales increase 7%, whilst skin cream Opzelura's sales rose 24%. The company expects about 10 clinical data readouts in the second half of fiscal 2026. It raised full-year fiscal 2026 sales guidance by 7% and lifted Opzelura outlook by roughly 40%.

Insider Monkey
Aug 30th, 2026
Josh Brown says 'take a break from AI capex world,' highlights his 2 top healthcare stock picks.

Josh Brown says 'take a break from AI capex world,' highlights his 2 top healthcare stock picks. Published on august 30, 2026 at 9:45 am by fahad saleem in hedge funds, news, stock analysis. In a recent interview on CNBC's Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his "Best Stocks in the Market." Brown said he wanted to focus on stocks that had "nothing to do" with the AI and data-center spending theme. "We wanted to do something that had nothing to do with data centers and GPUs and just take a break from that whole AI capex world that we've been living in for so long," Brown said. "We wanted to talk about stocks that are working away from that." Brown likes Biogen because of strong fundamentals and the company's strong earnings performance. But in this article, we will focus on Incyte, which is up 22% so far this year. Analyzing Incyte. Brown's bullish case for Incyte centers on its strong earnings momentum and expanding drug pipeline. Brown said the company has a pipeline of roughly nine or 10 drugs at various stages of development, creating multiple potential catalysts for future growth. Incyte Corporation (NASDAQ:INCY) develops drugs for blood cancers, solid tumors and inflammatory skin diseases. In the quarterly results reported in July, revenue rose 38% year over year and net product sales jumped 40%. Both metrics beat Wall Street estimates. Its key product is Jakafi, a pill that treats two blood cancers and a complication of bone marrow transplants. Jakafi sales rose 7% in the quarter, and the number of prescriptions filled rose 9%. Opzelura, a skin cream, saw sales rise 24% after removing one-time benefits. Bulls point to how diversified the company has become. Even when Jakafi loses exclusivity, the company is on track to reach $3 billion to $4 billion in net sales by 2030 from the rest of the portfolio. The company also raised its full-year fiscal 2026 sales guidance by about 7% and lifted the Opzelura outlook by roughly 40%. The company expects about 10 clinical data readouts in the second half of fiscal 2026, four of them from registrational trials, which could be strong catalysts. Bears point to Jakafi, which still accounts for a major chunk of net sales and could lose exclusivity in key regions in 2028. A lot depends on new launches and catalysts landing before then. Competition is coming. AbbVie recently won European Commission approval for Rinvoq in non-segmental vitiligo, which could put direct pressure on Opzelura's European vitiligo business.